Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Yehia I Mohamed"'
Autor:
Shadi Chamseddine, Betul Gok Yavuz, Yehia I. Mohamed, Sunyoung S. Lee, James C. Yao, Zishuo Ian Hu, Michael LaPelusa, Lianchun Xiao, Ryan Sun, Jeffrey S. Morris, Rikita I. Hatia, Manal Hassan, Dan G. Duda, Maria Diab, Amr Mohamed, Ahmed Nassar, Hesham M. Amin, Ahmed Omar Kaseb
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Vol 7, Iss 4, Pp 255-262 (2024)
Introduction: Galectin-3 plays critical roles in the adhesion, proliferation, and differentiation of tumor cells. Recent data have suggested that galectin-3 plays a role in the development of hepatocellular carcinoma (HCC); however, its prognostic va
Externí odkaz:
https://doaj.org/article/c7007e3fd8d74d43a19828dfc72d4de2
Autor:
Abdelrahim Maen, Betul Gok Yavuz, Yehia I. Mohamed, Abdullah Esmail, Jianming Lu, Amr Mohamed, Asfar S. Azmi, Mohamed Kaseb, Osama Kasseb, Dan Li, Michelle Gocio, Mehmet Kocak, Abdelhafez Selim, Qing Ma, Ahmed O. Kaseb
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Thymoquinone TQ, an active ingredient of Nigella Sativa, has been shown to inhibit COVID-19 symptoms in clinical trials. Thymoquinone Formulation (TQF or NP-101) is developed as a novel enteric-coated medication derivative from Nigella Sativa. TQF co
Externí odkaz:
https://doaj.org/article/1173d8f5ba9d4781bcf404aa0ad63ed4
Autor:
Y. Linda Wu, Grace van Hyfte, Umut Özbek, Marlene Reincke, Anuhya Gampa, Yehia I. Mohamed, Naoshi Nishida, Brooke Wietharn, Suneetha Amara, Pei-Chang Lee, Bernhard Scheiner, Lorenz Balcar, Matthias Pinter, Arndt Vogel, Arndt Weinmann, Anwaar Saeed, Anjana Pillai, Lorenza Rimassa, Abdul Rafeh Naqash, Mahvish Muzaffar, Yi-Hsiang Huang, Ahmed O. Kaseb, Masatoshi Kudo, David J. Pinato, Celina Ang
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundIn patients with cirrhosis, portal hypertension increases intestinal permeability, dysbiosis, and bacterial translocation, promoting an inflammatory state that can lead to the progression of liver disease and development of hepatocellular c
Externí odkaz:
https://doaj.org/article/5885bcec7b444fc4b4fe6d9c281e9f99
Autor:
Ahmed O. Kaseb, Abedul Haque, Deeksha Vishwamitra, Manal M. Hassan, Lianchun Xiao, Bhawana George, Vishal Sahu, Yehia I. Mohamed, Roberto Carmagnani Pestana, Jamie Lynne Lombardo, Rony Avritscher, James C. Yao, Robert A. Wolff, Asif Rashid, Jeffrey S. Morris, Hesham M. Amin
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Hepatocellular carcinoma (HCC) is an aggressive neoplasm with poor clinical outcome because most patients present at an advanced stage, at which point curative surgical options, such as tumor excision or liver transplantation, are not feasible. There
Externí odkaz:
https://doaj.org/article/224741d9023048d79f5c82c97fdcee84
Autor:
Hassan Bencheqroun, Yasir Ahmed, Mehmet Kocak, Enrique Villa, Cesar Barrera, Mariya Mohiuddin, Raul Fortunet, Emmanuel Iyoha, Deborah Bates, Chinedu Okpalor, Ola Agbosasa, Karim Mohammed, Stephen Pondell, Amr Mohamed, Yehia I. Mohamed, Betul Gok Yavuz, Mohamed O. Kaseb, Osama O. Kasseb, Michelle York Gocio, Peter Tsu-Man Tu, Dan Li, Jianming Lu, Abdulhafez Selim, Qing Ma, Ahmed O. Kaseb
Publikováno v:
Pathogens, Vol 11, Iss 5, p 551 (2022)
There is an urgent need for an oral drug for the treatment of mild to moderate outpatient SARS-CoV-2. Our preclinical and clinical study’s aim was to determine the safety and preliminary efficacy of oral TQ Formula (TQF), in the treatment of outpat
Externí odkaz:
https://doaj.org/article/5a4c673e2a994d5c95f182d7cdfb43f2
Autor:
Thomas Talbot, Antonio D'Alessio, Matthias Pinter, Lorenz Balcar, Bernhard Scheiner, Thomas U. Marron, Tomi Jun, Sirish Dharmapuri, Celina Ang, Anwaar Saeed, Hannah Hildebrand, Mahvish Muzaffar, Claudia A. M. Fulgenzi, Suneetha Amara, Abdul Rafeh Naqash, Anuhya Gampa, Anjana Pillai, Yinghong Wang, Uqba Khan, Pei‐Chang Lee, Yi‐Hsiang Huang, Bertram Bengsch, Dominik Bettinger, Yehia I. Mohamed, Ahmed Kaseb, Tiziana Pressiani, Nicola Personeni, Lorenza Rimassa, Naoshi Nishida, Masatoshi Kudo, Arndt Weinmann, Peter R. Galle, Ambreen Muhammed, Alessio Cortellini, Arndt Vogel, David J. Pinato
Publikováno v:
Liver International. 43:695-707
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de9627fb7cffc608fafa38ff052e6472
https://doi.org/10.1111/liv.15502
https://doi.org/10.1111/liv.15502
Autor:
Li Gu, Yahui Zhu, Maiya Lee, Albert Nguyen, Nicolas T. Ryujin, Jian Yu Huang, Shusil K. Pandit, Shadi Chamseddine, Lianchun Xiao, Yehia I. Mohamed, Ahmed O. Kaseb, Michael Karin, Shabnam Shalapour
Publikováno v:
Proceedings of the National Academy of Sciences. 120
Although viral hepatocellular carcinoma (HCC) is declining, nonviral HCC, which often is the end stage of nonalcoholic or alcoholic steatohepatitis (NASH, ASH), is on an upward trajectory. Immune checkpoint inhibitors (ICIs) that block the T cell inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9c15a6c17ee6d3215fe253d87434315
https://doi.org/10.1073/pnas.2300706120
https://doi.org/10.1073/pnas.2300706120
Autor:
Ahmed O. Kaseb, Yehia I. Mohamed, Alexandre E. Malek, Issam I. Raad, Lina Altameemi, Dan Li, Omar A. Kaseb, Safa A. Kaseb, Abdelhafez Selim, Qing Ma
Publikováno v:
Pathogens, Vol 10, Iss 3, p 379 (2021)
The novel coronavirus disease 2019 (COVID-19) pandemic has led to an unprecedented threat to the international community and raised major concerns in terms of public health safety. Although our current understanding of the complexity of COVID-19 path
Externí odkaz:
https://doaj.org/article/6b840d69bf0543e4bc09f75ad7f2e8c5
Autor:
Ahmed Omar Kaseb, Elshad Hasanov, Hop Sanderson Tran Cao, Lianchun Xiao, Jean-Nicolas Vauthey, Sunyoung S Lee, Betul Gok Yavuz, Yehia I Mohamed, Aliya Qayyum, Sonali Jindal, Fei Duan, Sreyashi Basu, Shalini S Yadav, Courtney Nicholas, Jing Jing Sun, Kanwal Pratap Singh Raghav, Asif Rashid, Kristen Carter, Yun Shin Chun, Ching-Wei David Tzeng, Divya Sakamuri, Li Xu, Ryan Sun, Vittorio Cristini, Laura Beretta, James C Yao, Robert A Wolff, James Patrick Allison, Padmanee Sharma
Publikováno v:
Lancet Gastroenterol Hepatol
Kaseb, A O, Hasanov, E, Cao, H S T, Xiao, L, Vauthey, J N, Lee, S S, Yavuz, B G, Mohamed, Y I, Qayyum, A, Jindal, S, Duan, F, Basu, S, Yadav, S S, Nicholas, C, Sun, J J, Singh Raghav, K P, Rashid, A, Carter, K, Chun, Y S, Tzeng, C W D, Sakamuri, D, Xu, L, Sun, R, Cristini, V, Beretta, L, Yao, J C, Wolff, R A, Allison, J P & Sharma, P 2022, ' Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma : a randomised, open-label, phase 2 trial ', The Lancet Gastroenterology and Hepatology, vol. 7, no. 3, pp. 208-218 . https://doi.org/10.1016/S2468-1253(21)00427-1
Kaseb, A O, Hasanov, E, Cao, H S T, Xiao, L, Vauthey, J N, Lee, S S, Yavuz, B G, Mohamed, Y I, Qayyum, A, Jindal, S, Duan, F, Basu, S, Yadav, S S, Nicholas, C, Sun, J J, Singh Raghav, K P, Rashid, A, Carter, K, Chun, Y S, Tzeng, C W D, Sakamuri, D, Xu, L, Sun, R, Cristini, V, Beretta, L, Yao, J C, Wolff, R A, Allison, J P & Sharma, P 2022, ' Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma : a randomised, open-label, phase 2 trial ', The Lancet Gastroenterology and Hepatology, vol. 7, no. 3, pp. 208-218 . https://doi.org/10.1016/S2468-1253(21)00427-1
Background: Hepatocellular carcinoma has high recurrence rates after surgery; however, there are no approved standard-of-care neoadjuvant or adjuvant therapies. Immunotherapy has been shown to improve survival in advanced hepatocellular carcinoma; we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38276e79aeed564d05882604eb17143a
https://doi.org/10.1016/s2468-1253(21)00427-1
https://doi.org/10.1016/s2468-1253(21)00427-1
Autor:
Thomas, Talbot, Antonio, D'Alessio, Matthias, Pinter, Lorenz, Balcar, Bernhard, Scheiner, Thomas U, Marron, Tomi, Jun, Sirish, Dharmapuri, Celina, Ang, Anwaar, Saeed, Hannah, Hildebrand, Mahvish, Muzaffar, Claudia A M, Fulgenzi, Suneetha, Amara, Abdul Rafeh, Naqash, Anuhya, Gampa, Anjana, Pillai, Yinghong, Wang, Uqba, Khan, Pei-Chang, Lee, Yi-Hsiang, Huang, Bertram, Bengsch, Dominik, Bettinger, Yehia I, Mohamed, Ahmed, Kaseb, Tiziana, Pressiani, Nicola, Personeni, Lorenza, Rimassa, Naoshi, Nishida, Masatoshi, Kudo, Arndt, Weinmann, Peter R, Galle, Ambreen, Muhammed, Alessio, Cortellini, Arndt, Vogel, David J, Pinato
Publikováno v:
Liver international : official journal of the International Association for the Study of the Liver.
Different approaches are available after progression of disease (PD) to immune checkpoint inhibitors (ICI) for hepatocellular carcinoma (HCC), including continuation of ICI, treatment switching to tyrosine kinase inhibitors (TKIs) and cessation of an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d8944728dea5a254b705401d192df2ff
https://pubmed.ncbi.nlm.nih.gov/36577703
https://pubmed.ncbi.nlm.nih.gov/36577703